LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology ‌research has told reporters, after early data showed the ...

When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets. | When it comes to GSK’s ...

As Reuters reports, Advair is an $8 billion drug for GSK. And GSK has invested heavily in several potential sequels to the blockbuster. In the U.S., the partners have asked the FDA to approve their ...

GSK Plc’s older respiratory medicines showed lackluster sales in the first quarter, leaving HIV and cancer drugs to drive ...

By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker will aim to lift sales growth and speed up work on new medicines in its ...